Theralase Technologies Inc. V.TLT

TLT 2022

[Mikee3003]

Our turn coming.....

12:44 PM EST, 03/04/2021 (MT Newswires) -- Amgen (AMGN) entered a $1.9-billion acquisition deal with Five Prime Therapeutics (FPRX) to strengthen its oncology portfolio and support its strategic global expansion, according to the companies' joint statement on Thursday.

Thousand Oaks, California-based Amgen will acquire Five Prime at $38 per share, a premium to the biotechnology company's closing price of $21.26 on Wednesday. The shares of South San Francisco, California-based Five Prime surged 78% on Thursday afternoon.

The deal includes Five Prime's bemarituzumab, a targeted antibody being developed for the treatment of gastric cancer. Amgen plans to expand its presence in the Asia-Pacific region, particularly in Japan, to boost the potential of the therapy.

 

[Rumpl3StiltSkin]

Yes and TLT's IP is worth more IMO, especially to Merck. They'd be smart to buy TLT to protect their Keytruda product.

[patience69]

I personally hate the thought of being bought to protect another drug. This is a new & potentially game breaking tx that needs to get out there & save lives asap 

[Rumpl3StiltSkin]

Yeah I know. I'd like it to get out there too. Yet if you are Merck and this comes out and approved, Break through, etc. One of your competitors will buy it. You can't have that. If Merck's bid is the final and largest then it will be at their leisure to bring it to market. If not then it will be out, like you say, asap. :-)

[99942Apophis]

If this is proved successful in trial it will be in the news whoever buys won't be able to hide it maybe slow it down a touch. Investigations will be hard and heavy if a large pharmaceutical tries to bury it. This is worth a lot of coin to the buyer. 

[Rumpl3StiltSkin]

"Slow it down a touch" Yep, I agree. IF Merck is the winner they will want this product out. But unlike competitors they will have a bunch of Keytruda 'stuff' they will have to walk away from.

[Mikee3003]

You got that right Rumpl... .Merck has the industry’s largest immuno-oncology clinical research program. There are currently more than 1,000 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with

[skys1]

I don't think things are going too well for the cancer drugs like Keytruda, Opdivo, Infinzi etc. Check out the latest stories and headlines of drug makers pulling their products of the shelves, due to lack of results plus flubed trials.  "Merck's Keytruda misses mark in small cell lung cancer trial, dasking big expansion hopes". or Bristiol Meyers pulling Opivo because of a

[skyhawk1]

That's WHY this is a PERRRRRFECT TIME & OPPORTUNITY for TLT to gain a BIG chunk of the market if our trials PREVAIL?!   The other BIG PHARMA treatments are mostly lots of HYPE with rather poor RESULTS!!  

[Rumpl3StiltSkin]

Yeah Skys, I have no idea how many patients will ultimately be treated in TLT's Phase 2? If it is more than 50 then I think the CR%s could be pretty huge. One of the above pharmas will want this tech. Both for NMIBC and many other indications. Hopefully TLT can arrange the bidding war that should ensue. I think sometime in 2022 the CR numbers will be in for at least 90day data on that 50 or